These cumulative findings prompted FDA label expansion in April 2019, authorizing pembrolizumab as primary therapy for metastatic NSCLC with PD‐L1 TPS ≥ 1% [24]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.